Arbutus Biopharma Corporation (ABUS) is a leading biotechnology business based in the US. Arbutus Biopharma is listed on the NASDAQ and employs 78 staff. All prices are listed in US Dollars.
|52-week range||$0.88 - $6.48|
|50-day moving average||$3.9942|
|200-day moving average||$3.3688|
|Wall St. target price||$7|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.79|
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|Revenue TTM||$6.1 million|
|Gross profit TTM||$-51,590,000|
|Return on assets TTM||-25.05%|
|Return on equity TTM||-78.86%|
|Market capitalisation||$343.9 million|
TTM: trailing 12 months
There are currently 4.8 million Arbutus Biopharma shares held short by investors – that's known as Arbutus Biopharma's "short interest". This figure is 63.5% up from 2.9 million last month.
There are a few different ways that this level of interest in shorting Arbutus Biopharma shares can be evaluated.
Arbutus Biopharma's "short interest ratio" (SIR) is the quantity of Arbutus Biopharma shares currently shorted divided by the average quantity of Arbutus Biopharma shares traded daily (recently around 5.5 million). Arbutus Biopharma's SIR currently stands at 0.87. In other words for every 100,000 Arbutus Biopharma shares traded daily on the market, roughly 870 shares are currently held short.
However Arbutus Biopharma's short interest can also be evaluated against the total number of Arbutus Biopharma shares, or, against the total number of tradable Arbutus Biopharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Arbutus Biopharma's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Arbutus Biopharma shares in existence, roughly 60 shares are currently held short) or 0.0717% of the tradable shares (for every 100,000 tradable Arbutus Biopharma shares, roughly 72 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Arbutus Biopharma.
Find out more about how you can short Arbutus Biopharma stock.
We're not expecting Arbutus Biopharma to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
Arbutus Biopharma's shares were split on a 1:5 basis on 4 November 2010. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Arbutus Biopharma shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for Arbutus Biopharma shares which in turn could have impacted Arbutus Biopharma's share price.
Over the last 12 months, Arbutus Biopharma's shares have ranged in value from as little as $0.88 up to $6.48. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Arbutus Biopharma's is 3.1565. This would suggest that Arbutus Biopharma's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-836, a capsid inhibitor that has the potential to inhibit HBV replication by preventing the assembly of functional viral capsids; and AB-423, which is in pre-clinical studies. The company also develops RNAi drugs, which utilize the RNA interference pathway, allows for a novel approach to treating disease. Its RNAi HBV candidates are designed to reduce hepatitis B surface antigen expression in patients chronically infected with HBV. In addition, it develops AB-729, a second generation RNAi therapeutic targeted to hepatocytes; HBV RNA destabilizer, an orally active agent that cause the destabilization of HBV RNAs, which leads to RNA degradation and to reduction in HBsAg levels. Further, the company engages conducting a Phase 1a/1b clinical trial and several pre-clinical and investigational new drug-enabling studies to evaluate proprietary HBV therapeutic agents, together with standard of care therapies, and in combination with each other. It has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc.; and Acuitas Therapeutics, Inc. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
Learn more about Transportation and Logistics Systems’ recent performance and where you can invest in Transportation and Logistics Systems shares. We also run through some helpful rules of thumb for any investor.
Learn more about Charlie’s Holdings’ recent performance and where you can invest in Charlie’s Holdings shares. We also run through some helpful rules of thumb for any investor.
Learn more about Lemonade’s recent performance and where you can invest in Lemonade shares. We also run through some helpful rules of thumb for any investor.
Learn more about Unity Software’s recent performance and where you can invest in Unity Software shares. We also run through some helpful rules of thumb for any investor
Learn more about FuelCell Energy’s recent performance and where you can invest in FuelCell Energy shares. We also run through some helpful rules of thumb for any investor.
Learn more about CloudCommerce’s recent performance and where you can invest in CloudCommerce shares. We also run through some helpful rules of thumb for any investor
Ever wondered how to buy shares in Zomedica Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Zomedica Pharmaceuticals.
Ever wondered how to buy shares in YRC Worldwide? We explain how and compare a range of providers that can give you access to many brands, including YRC Worldwide.
Ever wondered how to buy shares in Xeros Technology Group? We explain how and compare a range of providers that can give you access to many brands, including Xeros Technology Group.
Ever wondered how to buy shares in Xpediator? We explain how and compare a range of providers that can give you access to many brands, including Xpediator.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.